We use cookies to personalize content and ads, provide social media features, analyze our traffic, share information with our third-party partners or allow our third-party partners to collect information about your use of our site. For more information regarding our privacy practices and use of cookies, review our Privacy Policy.
Frontotemporal Dementia (FTD) upliFT-D (PBFT02) Clinical Trial
Information for healthcare providers
About our clinical trial
Our investigational gene therapy product candidate, PBFT02, uses an adeno-associated virus serotype 1 (AAV1) viral vector to deliver a functional GRN gene, encoding progranulin (PGRN), to a patient’s cells. The vector is delivered, with CT guidance, directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection).1-3
The goal of this vector and delivery approach is to provide elevated levels of PGRN to the central nervous system (CNS) to overcome the PGRN deficiency seen in GRN mutation carriers with FTD. upliFT-D will assess the safety, tolerability, and efficacy of this treatment in patients with FTD caused by a GRN mutation (FTD-GRN).1-4
upliFT-D clinical trial video
Watch Dr. Juan Chavez, Vice President of Clinical Development at Passage Bio, explain what the upliFT-D trial is, how it is design to study a potential new therapy for people living with FTD-GRN, and how Passage Bio can help support both patients and caregivers throughout the clinical trial. This video serves as an informative tool to use with patients when discussing their options.
Understand more about an FTD diagnosis, Passage Bio clinical trial options, and the FTD patient/care partner community.
Download the
FTD-GRN patient brochure 
Gain insight into the disease progression of FTD-GRN, the role of progranulin, and the therapeutic potential of PBFT02.
Download the
FTD-GRN brochure for healthcare providers
Inclusion criteria1
-
Aged ≥35 and
≤75 years -
Clinical diagnosis of early symptomatic FTD
-
Documented to be a pathogenic GRN mutation carrier
-
Have a reliable informant/caregiver who personally speaks with or sees the patient at least weekly
-
Living in the community (ie, not in a nursing home); assisted living may be permitted at the discretion of the investigator
Study design1,3
upliFT-D is a Phase 1/2 global, multi-center, open-label, clinical trial of PBFT02 administered by a one-time ICM injection in patients with FTD-GRN. This trial will assess the safety, tolerability, and efficacy of PBFT02 in patients with FTD-GRN.1
- The upliFT-D clinical trial will enroll up to 15 patients across 3 cohorts3
- An optional third cohort may be enrolled based on the results of the first 2 cohorts1
- This is a 5-year study, with a 2-year main study, followed by a 3-year safety extension1
Best-in-class potential
Interim results from the trial demonstrated that PBFT02 achieved consistent PGRN elevation at 6 months post-treatment in two patients, underscoring the differentiated profile of PBFT02.3
Genetic testing available at no cost
Genetic testing programs are available to help you confirm FTD-GRN:
Visit InformedDNA to refer your US-based patients to no-cost genetic testing and counseling*† 
No-cost genetic testing is available in all markets with Prevention Genetics†
*InformedDNA no-cost genetic testing and counseling is only available to US residents.
†While the FTD sponsored testing programs are sponsored by Passage Bio, no personal identifying information of individuals participating in these genetic testing programs will be shared with the company.
Is your patient right for the upliFT-D trial?
Have you confirmed your patient has FTD-GRN via genetic testing?
Refer patient to a sponsored
genetic testing program.Did the results confirm FTD-GRN?
Refer patient to a trial
site location for further eligibility assessment
Patient is ineligible for
the upliFT-D trial
How to refer a patient to the upliFT-D trial
- Referring a patient to the nearest trial site can be coordinated by contacting the trial team directly to assess qualified patients for further eligibility
- Please note that all trial-related costs, including travel, will be covered by Passage Bio
-
For more inquiries on the upliFT-D trial, email
[email protected] -
Click here for more information on active trial sites
References: 1. A study of PBFT02 in patients with frontotemporal dementia and progranulin mutations (FTD-GRN) (upliFT-D). ClinicalTrials.gov identifier: NCT04747431. Updated April 18, 2024. Accessed June 26, 2024. https://clinicaltrials.gov/study/NCT04747431 2. Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10(2):119. doi:10.3390/brainsci10020119 3. Data on file. Passage Bio; Philadelphia, PA. 4. Anderson KM, McNeil E, Weinstein DA, Romano G. Gene therapy for treatment of monogenic neurodegenerative diseases. Neurol Reviews. 2021;(suppl):S1-S7.
Passage Bio is a genetics medicine company focused on developing transforming therapies for central nervous system (CNS) disorders
1835 Market Street, Suite 1100 Philadelphia, PA 19103 | PassageBio.com | © Passage Bio, Inc. All rights reserved.
WW-FTD-033-09132025
